标题
A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells
作者
关键词
-
出版物
CELL CYCLE
Volume 15, Issue 4, Pages 573-583
出版商
Informa UK Limited
发表日期
2016-01-22
DOI
10.1080/15384101.2016.1138183
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
- (2016) Linda S. Steelman et al. Aging-US
- Pro-senescence therapy for hepatocellular carcinoma
- (2016) Susanne Muehlich et al. Aging-US
- Mutant lamin A links prophase to a p53 independent senescence program
- (2015) Olga Moiseeva et al. CELL CYCLE
- Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells
- (2015) Antonella Cusimano et al. Oncotarget
- Leptin and Neutrophil-Activating Peptide 2 Promote Mesenchymal Stem Cell Senescence Through Activation of the Phosphatidylinositol 3-Kinase/Akt Pathway in Patients With Systemic Lupus Erythematosus
- (2015) Haifeng Chen et al. Arthritis & Rheumatology
- Targeted therapy for hepatocellular carcinoma: novel agents on the horizon
- (2015) Melchiorre Cervello et al. Oncotarget
- The AKT Inhibitor MK-2206 is Cytotoxic in Hepatocarcinoma Cells Displaying Hyperphosphorylated AKT-1 and Synergizes with Conventional Chemotherapy
- (2015) Carolina Simioni et al. Oncotarget
- Treating advanced hepatocellular carcinoma: How to get out of first gear
- (2014) James J. Harding et al. CANCER
- ERKs in Cancer: Friends or Foes?
- (2014) Xavier Deschênes-Simard et al. CANCER RESEARCH
- Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
- (2014) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- TAT-Protein Blockade during Ischemia/Reperfusion Reveals Critical Role for p85 PI3K-PTEN Interaction in Cardiomyocyte Injury
- (2014) Xiangdong Zhu et al. PLoS One
- Senescence and aging: the critical roles of p53
- (2013) A Rufini et al. ONCOGENE
- PTEN regulation of ERK1/2 signaling in cancer
- (2012) Mahandranauth A. Chetram et al. JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION
- Hepatocellular carcinoma
- (2012) Alejandro Forner et al. LANCET
- Senescence: a new weapon for cancer therapy
- (2012) Juan Carlos Acosta et al. TRENDS IN CELL BIOLOGY
- Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma
- (2011) Qian Zhou et al. Future Oncology
- A continuum model for tumour suppression
- (2011) Alice H. Berger et al. NATURE
- AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy
- (2011) M V Astle et al. ONCOGENE
- Phosphatidylinositol(4,5)bisphosphate coordinates actin-mediated mobilization and translocation of secretory vesicles to the plasma membrane of chromaffin cells
- (2011) Peter J. Wen et al. Nature Communications
- PTEN inhibitors cause a negative inotropic and chronotropic effect in mice
- (2010) Lingyun Zu et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis
- (2010) Andrea Alimonti et al. JOURNAL OF CLINICAL INVESTIGATION
- Therapy-Induced Senescence in Cancer
- (2010) Jonathan A. Ewald et al. JNCI-Journal of the National Cancer Institute
- Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence
- (2010) Hui-Kuan Lin et al. NATURE
- Subtle variations in Pten dose determine cancer susceptibility
- (2010) Andrea Alimonti et al. NATURE GENETICS
- ERK and cell death: Mechanisms of ERK-induced cell death - apoptosis, autophagy and senescence
- (2009) Sebastien Cagnol et al. FEBS Journal
- Targeting mitogen-activated protein kinase kinase with the inhibitor PD0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model systems
- (2009) Matthew Hennig et al. HEPATOLOGY
- Akt Determines Replicative Senescence and Oxidative or Oncogenic Premature Senescence and Sensitizes Cells to Oxidative Apoptosis
- (2008) Veronique Nogueira et al. CANCER CELL
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now